versions of Combigan until its patent expiration in 2022. On February 2, 2022, Carlisle Medical issued a press release announcing that Apotex Corporation has launched the authorized generic version of Combigan (Brimonidine Timolol OPSO 0.2%/0.5%) in the United States subsequent to the FDA'a approval of the generic on December 13, 2021. On April 14, 2022, Novartis' Sandoz, Inc. issue a press release announcing the US launch of its generic combination. References Ophthalmology drugs Combination drugs AbbVie brands